Our main passion is to improve the lives of our patients.
NNI researchers pursue scientific innovation to advance the care for patients beyond the clinical treatment that they receive. The main driver for these researchers is their drive and commitment to improve the lives of NNI patients.
Development of Mini Brains – Parkinson's Disease Research
The NNI Parkinson Disease research team has been advancing the understanding of Parkinson's Disease through research and clinical investigation. Led by Prof Tan Eng King, Deputy Medical Director and Director, Research, NNI, and his team consisting of A/Prof Louis Tan, Deputy Director, Research, NNI, A/Prof Lim Kah Leong, Visiting Lead Scientist, NNI and Prof Ng Huck Hui, Executive Director, Genome Institute of Singapore, A*STAR, the team has developed new therapies for Parkinson's Disease, arising from their research outcomes.
The team successfully recreated the first-in-the-world miniature version of the human midbrain, a command centre managing our vision, hearing and body movements. At the size of a rice grain, it performs the actual function of the human midbrain. This allows researchers to test how the midbrain react to drugs before treating patients.
The team’s work exemplifies the concept and significance of actualising ‘bench-to-bedside’, from research endeavours to patient outcomes.
Precision Medicine – NNI Neuro-oncology Research Programme
The NNI neuro-oncology research team has led groundbreaking findings over the past 10 years, establishing a resource of archived patient tumors, primary cell lines and animal tumor models. In recent years, the team published significant findings suggesting novel therapeutic pathways. The team was awarded the Translational and Clinical Research (TCR) Flagship Program grant in 2016 by the National Medical Research Council. This award is the nation’s highest level of funding conferred based on the program’s international competitiveness for the translation of basic scientific discoveries o the clinic.
Click here to donate today and support our researchers on their quest for a new cure.
Subcribe to our mailing list to get the updates to your email inbox...
Best viewed on IE 11, Firefox 27, Chrome 22, and Safari 7 and above.